Evidence map›Paper›PMID 41567212›Full record

ArticleFrontiers in immunology2025

Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study.

Shuaipeng He, Cheng Wang, Xuan Li, Can Li, Dan Li, Biao Zhang, Jianghou Wan, Zhongjin Yue, Gongjin Wu, Su Zhang and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuaipeng He *Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Cheng Wang *Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Xuan LiDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Can LiDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Dan LiDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Biao ZhangDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Jianghou WanDepartment of Urology, The First Hospital of Lanzhou University, Lanzhou, China.
Zhongjin YueDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Gongjin WuDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Su ZhangDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Junhai MaDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.
Panfeng ShangDepartment of Urology, The Second Hospital of Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Disitamab vedotin (RC48) is a HER2-targeted antibody-drug conjugate (ADC) that can induce immunogenic cell death and enhance antitumor immunity. Preclinical data suggest synergistic activity with PD-1 inhibitors, but its benefit in upper tract urothelial carcinoma (UTUC) remains unclear. This study evaluated the efficacy and safety of RC48, as monotherapy or combined with PD-1 blockade, in advanced UTUC. Methods: We conducted a multicenter retrospective study of patients with locally advanced or metastatic UTUC treated with RC48 ± PD-1 inhibitors. Baseline features and adverse events (AEs) were summarized descriptively. Objective response rate (ORR) and disease control rate (DCR) were calculated with exact 95% confidence intervals. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier and compared with the log-rank test. Multivariable Cox models included covariates significant in univariable analyses. Results: A total of 41 patients were analyzed (9 monotherapy, 32 combination). Median follow-up was 16.5 months. The 12-month OS rate was 92.3%, and the 24-month OS rate was 63.2%; median OS was not reached. Median PFS was 12.6 months, with 6- and 12-month PFS rates of 78.0% and 56.4%, respectively. In an exploratory subgroup analysis, the 12-month PFS rate was 68.9% for first-line treatment versus 36.5% for later lines (p = 0.031). Among 22 patients with measurable lesions, ORR was 40.9% (9/22) and DCR was 81.8% (18/22). In the overall cohort of 41 patients, grade ≥3 AEs occurred in 18.8% (6/32) of patients in the combination group, including one grade 4 Stevens-Johnson syndrome. Conclusion: RC48, used alone or in combination with PD-1 inhibitors, showed preliminary antitumor activity with manageable toxicity in patients with locally advanced or metastatic UTUC in this multicenter real-world cohort.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellImmune Checkpoint InhibitorsUrologic NeoplasmsAdultAgedAged, 80 and overAntibodies, MonoclonalFemaleHumansMaleMiddle AgedNeoplasm MetastasisOligopeptidesProgrammed Cell Death 1 ReceptorRetrospective StudiesAntibodies, Monoclonaldisitamab vedotinImmune Checkpoint InhibitorsOligopeptidesPDCD1 protein, humanProgrammed Cell Death 1 Receptorantibody–drug conjugatedisitamab vedotinHER2immunotherapyreal-world studyupper tract urothelial carcinoma

Identifiers

PMID41567212
PMCPMC12816211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.